Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Begona Barroso-Fernandez"'
Autor:
Jan van Dijk, Dorien Groenendaal-van de Meent, Martin den Adel, Georg Golor, Marloes Schaddelee, Begona Barroso-Fernandez, Virginie Kerbusch
Publikováno v:
Clinical Therapeutics. 43:1079-1091
Purpose Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, treats anemia in chronic kidney disease. Hyperphosphatemia, a common complication in chronic kidney disease, is treated with phosphate binders (PBs). This study in healthy i
Autor:
Rudiger Kaspera, Gernot K Klein, Begona Barroso-Fernandez, Virginie Kerbusch, Dorien Groenendaal-van de Meent, Martin den Adel, Piergiorgio Galletti
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Background and Objectives Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for anemia in chronic kidney disease. The pharmacokinetics, metabolic profile, and pharmacodynamics of roxadustat were investigated in subj
Autor:
Rudiger Kaspera, Martin den Adel, Gernot K Klein, Virginie Kerbusch, Begona Barroso-Fernandez, Piergiorgio Galletti, Dorien Groenendaal-van de Meent
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor used at titrated doses to treat anaemia in CKD patients. This study investigated the pharmacokinetics (PK), metabolic profile, pharmacodynamics,
Autor:
Dorien Groenendaal-van de Meent, Jan van Dijk, Rachid El Galta, Georg Golor, Marloes Schaddelee, Begona Barroso-Fernandez, Martin den Adel
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Background and Objectives Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease. This study investigated the effect of multiple daily oral doses of omeprazole on the